The latest price target for Castle Biosciences (NASDAQ:CSTL) was reported by Roth Capital on June 25, 2026. The analyst firm set a price target for $40.00 expecting CSTL to rise to within 12 months (a possible 67.40% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Castle Biosciences (NASDAQ:CSTL) was provided by Roth Capital, and Castle Biosciences initiated their buy rating.

There is no last upgrade for Castle Biosciences

There is no last downgrade for Castle Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Castle Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Castle Biosciences was filed on June 25, 2026 so you should expect the next rating to be made available sometime around June 25, 2027.

While ratings are subjective and will change, the latest Castle Biosciences (CSTL) rating was a initiated with a price target of $0.00 to $40.00. The current price Castle Biosciences (CSTL) is trading at is $23.90, which is within the analyst’s predicted range.